Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Patients will be enrolled from the offices of university or community urologists/oncologists across Canada treating patients with PCa.

Inclusion Criteria:

i. Adult > 18 years old

ii. Has provided written informed consent allowing the use of their data for the study and providing permission for contact by the study personnel

iii. Diagnosed with Prostate Cancer

iv. Prescribed Lupron as part of his treatment by his treating physician

Exclusion Criteria:

i. Currently participating in another prospective study including controlled clinical trials and observational studies.

• Exclusion of patient participating in other observational studies is necessary in order to prevent over-representation of specific patients in different studies, practical considerations regarding authority to utilize the patient's data and statistical issues related to lack of independence of the observations in different studies triggering multiplicity issues

ii. Patient cannot or will not sign informed consent

iii. Survival expectancy less than 2-3 years as per the treating physician's judgment

iv. Presence of other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of Prostate Cancer

v. History of alcohol or drug abuse

vi. No longer than 6 months of therapy if currently on luteinizing hormone-releasing hormone (LHRH) treatment